EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antifibrotic effects of specific targeting of the 5‐hydroxytryptamine 2B receptor (5‐HT 2B R) in murine models and ex vivo models of scleroderma skin

Thuong Trinh-Minh, Cuong Tran-Manh, Andrea-Hermina Györfi iD, Nicholas Dickel, Christoph Liebel, Xiang Zhou, Jiucun Wang iD, Meik Kunz, Helena Arozenius, Lars Pettersson, Sam Lindgren, Christina Wenglén und 1 weitere

Arthritis & Rheumatology · 2025

DOI: 10.1002/art.43151 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2025. Verfasst von Thuong Trinh-Minh und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospit…. Hauptthemen laut MEDLINE: Scleroderma, Systemic, Skin, Pulmonary Fibrosis, Receptor, Serotonin, 5-HT2B. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Wilhelm Sander-Stiftung, Else Kröner-Fresenius-Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Systemic sclerosis (SSc) is a connective tissue disease with fibrotic remodeling of the skin and various internal organs. SSc is associated with the highest case‐specific mortality of all rheumatic autoimmune diseases with limited antifibrotic treatment options. Here, we evaluated the therapeutic effects of the highly selective 5‐hydroxytryptamine 2B receptor (5‐HT 2B R) inhibitor AM1476.

Methods

The antifibrotic effects of AM1476 were evaluated in the mouse models of bleomycin‐induced pulmonary fibrosis in Tsk‐1 mice and in mice with sclerodermatous chronic graft‐versus‐host disease. For further validation, the antifibrotic effects of AM1476 were analyzed in precision cut skin (PCS) slices from patients with SSc.

Results

AM1476 demonstrated high selectivity for 5‐HT 2B R over more than 200 other receptors, including other 5‐HT receptors in vitro. AM1476 reduced accumulation of hydroxyproline and fibrotic tissue remodeling of skin and/or lungs in all three mouse models at well‐tolerated doses with a comparable efficacy to that of nintedanib. In PCS of SSc skin, treatment with AM1476 reduced the expression of SSc‐specific signature genes. AM1476 demonstrated more pronounced regulation of terms related to fibroblast activation and fibrotic remodeling than mycophenolate mofetil.

Conclusion

We describe AM1476 as a highly selective inhibitor of 5‐HT 2B R. Treatment with AM1476 ameliorated fibrosis in three mouse models of SSc and normalized the expression of fibrosis‐related genes directly in SSc skin. Because AM1476 also demonstrated good tolerability in a phase 1 trial, further clinical trials with AM1476 are currently in the planning stage.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Scleroderma, SystemicSkinPulmonary FibrosisReceptor, Serotonin, 5-HT2BSerotonin 5-HT2 Receptor AntagonistsAnimalsMiceDisease Models, AnimalBleomycinHumansGraft vs Host DiseaseFibrosisFemale

Substanzen

BleomycinReceptor, Serotonin, 5-HT2BSerotonin 5-HT2 Receptor Antagonists

Autor:innen und Institutionen

  • Department of Rheumatology, University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany.
  • Chair of Medical Informatics, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Germany.
  • State Key Laboratory of Genetic Engineering, School of Life Sciences and Human Phenome Institute, Fudan University, Shanghai, China.
  • AnaMar AB, Stockholm, Sweden.

ORCID-Profile: Andrea-Hermina Györfi, Jiucun Wang, Jörg H W Distler

Förderung

  • Deutsche Forschungsgemeinschaft
  • Wilhelm Sander-Stiftung
  • Else Kröner-Fresenius-Stiftung
  • German Federal Ministry of Education and Research (BMBF)
  • Career Support Award of Medicine of the Ernst Jung Foundation and an unrestricted research grant from the Hiller-Foundation.
  • ELAN-Foundation Erlangen
  • Medical Faculty of Heinrich-Heine University Düsseldorf (FoKo)
  • AnaMar

Zitieren

APA

Trinh-Minh, T., Tran-Manh, C., Györfi, A. H., Dickel, N., Liebel, C., Zhou, X., Wang, J., Kunz, M., Arozenius, H., Pettersson, L., Lindgren, S., Wenglén, C., & Distler, J. H. W. (2025). Antifibrotic effects of specific targeting of the 5‐hydroxytryptamine 2B receptor (5‐HT 2B R) in murine models and ex vivo models of scleroderma skin. Arthritis & Rheumatology. https://doi.org/10.1002/art.43151

Vancouver

Trinh-Minh T, Tran-Manh C, Györfi AH, Dickel N, Liebel C, Zhou X, et al. Antifibrotic effects of specific targeting of the 5‐hydroxytryptamine 2B receptor (5‐HT 2B R) in murine models and ex vivo models of scleroderma skin. Arthritis & Rheumatology. 2025. doi:10.1002/art.43151

BibTeX
@article{TrinhMinh2025,
  author = {Trinh-Minh, Thuong and Tran-Manh, Cuong and Györfi, Andrea-Hermina and Dickel, Nicholas and Liebel, Christoph and Zhou, Xiang and Wang, Jiucun and Kunz, Meik and Arozenius, Helena and Pettersson, Lars and Lindgren, Sam and Wenglén, Christina and Distler, Jörg H W},
  title = {Antifibrotic effects of specific targeting of the 5‐hydroxytryptamine 2B receptor (5‐HT 2B R) in murine models and ex vivo models of scleroderma skin},
  journal = {Arthritis & Rheumatology},
  year = {2025},
  doi = {10.1002/art.43151}
}
Kostenlos starten →